Menu
Search
|

Menu

Close
X

Rocket Pharmaceuticals Inc RCKT.OQ (NASDAQ Stock Exchange Global Market)

17.19 USD
-0.42 (-2.39%)
As of Feb 17
chart
Previous Close 17.61
Open 17.62
Volume 71,086
3m Avg Volume 67,068
Today’s High 18.03
Today’s Low 16.75
52 Week High 19.70
52 Week Low 3.40
Shares Outstanding (mil) 27.01
Market Capitalization (mil) 70.77
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-3.648
FY16
-6.407
FY15
-12.564
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
1.23
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
85.59
16.52
LT Debt to Equity (MRQ)
vs sector
85.59
12.22
Return on Investment (TTM)
vs sector
-40.76
14.43
Return on Equity (TTM)
vs sector
-54.04
16.13

EXECUTIVE LEADERSHIP

J. Martin Carroll
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
David Southwell
President, Chief Executive Officer, Director, Since 2014
Salary: $465,508.00
Bonus: $221,231.00
John Militello
Principal Financial Officer, Principal Accounting Officer, Controller, Since 2018
Salary: --
Bonus: --
Rudolf Baumgartner
Executive Vice President, Chief Medical Officer, Since 2007
Salary: $393,095.00
Bonus: $144,538.00
Dale Ritter
Treasurer, Secretary, Since 2018
Salary: $274,093.00
Bonus: $86,384.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

430 E 29th St Ste 1040
NEW YORK   NY   10016-8367

Phone: +1646.4409100

Rocket Pharmaceuticals, Inc., formerly Inotek Pharmaceuticals Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye's natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye's trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination (FDC), of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases.

SPONSORED STORIES